Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
The Oncologist · 2023
DOI: 10.1093/oncolo/oyac186 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Bradley McGregor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Background
Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted using patient-level data for the nivolumab-based therapies and published data for the pembrolizumab-based therapies. First, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib using data from the CheckMate 214 (median follow-up [mFU]: 13.1 months), CheckMate 9ER (mFU: 12.8 months), and KEYNOTE-426 (mFU: 12.8 months) trials, respectively. Second, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib using data from the CheckMate 214 (mFU: 26.7 months), CheckMate 9ER (mFU: 23.5 months), and KEYNOTE-581 (mFU: 26.6 months) trials, respectively. Per-patient costs for all-cause and treatment-related grade 3/4 AEs with corresponding any-grade AE rates ≥ 20% were calculated based on the Healthcare Cost and Utilization Project database and inflated to 2020 US dollars.
Results
Per-patient all-cause grade 3/4 AE costs for nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib were $2703 vs. $4508 vs. $5772, and treatment-related grade 3/4 AE costs were $741 vs. $2722 vs. $4440 over ~12.8 months of FU. For nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib, per-patient all-cause grade 3/4 AE costs were $3120 vs. $5800 vs. $9285, while treatment-related grade 3/4 AE costs were $863 vs. $3162 vs. $5030 over ~26.6 months of FU.
Conclusion
Patients with aRCC treated with first-line nivolumab-based therapies had lower grade 3/4 all-cause and treatment-related AE costs than pembrolizumab-based therapies, suggesting a more favorable cost-benefit profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Fox Chase Cancer Center, Philadelphia, PA, USA.
- Bradford Hill Clinical Research Center, Santiago, Chile.
- University of Bari "A. Moro," and Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy.
- Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain.
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
ORCID-Profile: Bradley McGregor
Förderung
- Bristol Myers Squibb
Zitieren
APA
McGregor, B., Geynisman, D. M., Burotto, M., Porta, C., Suarez, C., Bourlon, M. T., Del Tejo, V., Du, E. X., Yang, X., Sendhil, S. R., Betts, K. A., & Huo, S. (2023). Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyac186
Vancouver
McGregor B, Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, et al. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. The Oncologist. 2023. doi:10.1093/oncolo/oyac186
BibTeX
@article{McGregor2023,
author = {McGregor, Bradley and Geynisman, Daniel M and Burotto, Mauricio and Porta, Camillo and Suarez, Cristina and Bourlon, Maria T and Del Tejo, Viviana and Du, Ella X and Yang, Xiaoran and Sendhil, Selvam R and Betts, Keith A and Huo, Stephen},
title = {Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyac186}
}
EUVIMED